Vocimagene Amiretrorepvec Plus Flucytosine vs Standard of Care Following Tumor Resection in Patients With Recurrent High-Grade Glioma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial
JAMA Oncol 2020 Oct 29;[EPub Ahead of Print], TF Cloughesy, K Petrecca, T Walbert, N Butowski, M Salacz, J Perry, D Damek, D Bota, C Bettegowda, JJ Zhu, F Iwamoto, D Placantonakis, L Kim, B Elder, G Kaptain, D Cachia, Y Moshel, S Brem, D Piccioni, J Landolfi, CC Chen, H Gruber, A Rao, D Hogan, W Accomando, D Ostertag, TT Montellano, T Kheoh, F Kabbinavar, MA VogelbaumFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.